Company intelligence / Profile preview
ExoRNA Bioscience
Shenzhen*, Guangdong Sheng, Chinaexornabio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
The company’s lead asset, ER‑2001, is in Phase 1 trials for Huntington Disease to evaluate safety, tolerability, pharmacokinetics/dynamics, and early efficacy signals using an intravenous exosome-based siRNA approach targeting LAMP‑2. No published efficacy results yet; trial ongoing/recruiting as of April 2025
- Therapeutic areas
- Neurology
- Modalities
- siRNA (small interfering RNA)Nucleic acid drugs delivered via exosome platform
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on ExoRNA Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExoRNA Bioscience.